Nony; Emmanuel

Patent Applications and Registrations

Patent applications and USPTO patent grants for Nony; Emmanuel.The latest application filed is for "monoclonal antibodies with enhanced adcc function".

Company Profile

5.39.35

Nony; Emmanuel - Antony FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Markers of immune response Grant 11,015,221 - Mascarell , et al. May 25, 2	2021-05-25
Sialylated fetuin-A as a marker of immunotherapy efficacy Grant 10,884,002 - Lombardi , et al. January 5, 2	2021-01-05
Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units Grant 10,364,425 - Chtourou , et al.	2019-07-30
Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units Grant 10,344,272 - Chtourou , et al. July 9, 2	2019-07-09
Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy Grant 10,190,166 - Moingeon , et al. Ja	2019-01-29
Biomarkers of immunotherapy efficacy Grant 10,101,341 - Bodo , et al. October 16, 2	2018-10-16
Monoclonal antibodies with enhanced ADCC function Grant 10,081,683 - Beliard , et al. September 25, 2	2018-09-25
Use of ADCC-optimized antibodies for treating low-responder patients Grant 9,879,089 - Bourel , et al. January 30, 2	2018-01-30
Recombinant Der P 2 expressed in Pichia Pastoris as a "natural-like" allergen for immunotherapy and diagnostic purposes Grant 9,868,770 - Bordas , et al. January 16, 2	2018-01-16
Monoclonal Antibodies With Enhanced Adcc Function App 20180002442 - BELIARD; ROLAND ; et al.	2018-01-04
Sialylated Fetuin-a As A Marker Of Immunotherapy Efficacy App 20170370946 - LOMBARDI; Vincent ; et al.	2017-12-28
Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa Grant 9,822,185 - Batard , et al. November 21, 2	2017-11-21
Markers Of Immune Response App 20170233816 - MASCARELL; Laurent ; et al.	2017-08-17
Monoclonal antibodies with enhanced ADCC function Grant 9,718,890 - Beliard , et al. August 1, 2	2017-08-01
Monoclonal antibodies with enhanced ADCC function Grant 9,718,889 - Beliard , et al. August 1, 2	2017-08-01
Monoclonal antibodies with enhanced ADCC function Grant 9,708,409 - Beliard , et al. July 18, 2	2017-07-18
Composition Of Allergen Extracts Having Reduced Toxicity And Method Of Production Thereof App 20170157240 - NONY; Emmanuel ; et al.	2017-06-08
Use Of Igg1 Immunoglobulins And/or Ligands Of The Cd32 Receptor For Treating Inflammatory Diseases And Incidents Via The Mucosa App 20160032018 - Batard; Thierry ; et al.	2016-02-04
Use of IgG.sub.1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route Grant 9,187,568 - Batard , et al. November 17, 2	2015-11-17
Use Of Adcc-optimized Antibodies For Treating Weak Patients App 20150307624 - Bourel; Dominique ; et al.	2015-10-29
Monoclonal Antibodies With Enhanced Adcc Function App 20150266972 - BELIARD; Roland ; et al.	2015-09-24
Use of ADCC-optimized antibodies for treating weak patients Grant 9,109,020 - Bourel , et al. August 18, 2	2015-08-18
Novel Allergen From Ragweed Pollen And Uses Thereof App 20150210742 - Bordas; Veronique ; et al.	2015-07-30
Monoclonal Antibodies With Enhanced Adcc Function App 20150152189 - Beliard; Roland ; et al.	2015-06-04
Methods For Identifying Dendritic Cell Subsets, For Determining If A Patient Is Developing A Regulatory Or An Effector Immune Response, And For Determining Response To Immunotherapy App 20140377761 - Moingeon; Philippe ; et al.	2014-12-25
Monoclonal Antibodies With Enhanced Adcc Function App 20140162356 - Beliard; Roland ; et al.	2014-06-12
Biomarkers Of Immunotherapy Efficacy App 20140112955 - Bodo; Veronique ; et al.	2014-04-24
Recombinant Or Transgenic Factor Vii Composition, Each Factor Vii Molecule Having Two N-glycosylation Sites With Defined Glycan Units App 20140093491 - Chtourou; Abdessatar Sami ; et al.	2014-04-03
Monoclonal antibodies with enhanced ADCC function Grant 8,685,725 - Beliard , et al. April 1, 2	2014-04-01
Method for grass species identification Grant 8,632,993 - Moingeon , et al. January 21, 2	2014-01-21
Use Of Adcc-optimized Antibodies For Treating Weak Patients App 20140017243 - Bourel; Dominique ; et al.	2014-01-16
Use of ADCC-optimized antibodies for treating weak patients Grant 8,501,171 - Bourel , et al. August 6, 2	2013-08-06
Recombinant Or Transgenic Factor Vii Compound Having A Majority Of Glycan, Biantennary, Bisialylated And Non-fucosylated Forms App 20130189244 - Chtourou; Abdessatar Sami ; et al.	2013-07-25
Monoclonal antibodies with enhanced ADCC function Grant 8,409,572 - Beliard , et al. April 2, 2	2013-04-02
Anti-D monoclonal antibodies Grant 8,357,370 - Beliard , et al. January 22, 2	2013-01-22
Anti-d Monoclonal Antibodies App 20120258096 - Beliard; Roland ; et al.	2012-10-11
Monoclonal Antibodies With Enhanced Adcc Function App 20120259095 - Beliard; Roland ; et al.	2012-10-11
Method for Grass Species Identification App 20120171710 - Moingeon; Philippe ; et al.	2012-07-05
Use Of Igg1 Immunoglobulins And/or Ligands Of The Cd32 Receptor For Treating Inflammatory Diseases And Manifestations Via The Mucosal Route App 20120171198 - Batard; Thierry ; et al.	2012-07-05
Method for treating infectious disease using monoclonal antibodies Grant 8,178,093 - Beliard , et al. May 15, 2	2012-05-15
Method for treating cancer using monoclonal antibodies Grant 8,153,124 - Beliard , et al. April 10, 2	2012-04-10
Method for treating idiopathic thrombocytopenic purpura using monoclonal antibodies Grant 8,124,078 - Beliard , et al. February 28, 2	2012-02-28
Recombinant Der P 2 Expressed in Pichia Pastoris as a "Natural-Like" Allergen for Immunotherapy and Diagnostic Purposes App 20110293665 - BORDAS; Veronique ; et al.	2011-12-01
Monoclonal Antibodies With Enhanced Adcc Function App 20110223658 - Beliard; Roland ; et al.	2011-09-15
Modified Human Factor Vii/viia And Pharmaceutical Composition Containing The Same App 20110162094 - Nony; Emmanuel ; et al.	2011-06-30
Monoclonal antibodies with enhanced ADCC function Grant 7,931,895 - Beliard , et al. April 26, 2	2011-04-26
Method For Treating Infectious Disease Using Monoclonal Antibodies App 20110059073 - BELIARD; ROLAND ; et al.	2011-03-10
Method For Treating Cancer Using Monoclonal Antibodies App 20110059072 - Beliard; Roland ; et al.	2011-03-10
Method For Treating Idiopathic Thrombocytopenic Purpura Using Monoclonal Antibodies App 20110052571 - Beliard; Roland ; et al.	2011-03-03
Cytokine production-inducing antibody App 20100323368 - de Romeuf; Christophe ; et al.	2010-12-23
Use of ADCC-Optimized antibodies for treating weak patients App 20100303826 - Bourel; Dominique ; et al.	2010-12-02
Preparation of human, humanized or chimaeric antibodies or polypeptides having different binding profiles to Fcgamma receptors Grant 7,790,399 - Bourel , et al. September 7, 2	2010-09-07
Use of ADCC-optimized antibodies for treating low-responder patients Grant 7,713,524 - Bourel , et al. May 11, 2	2010-05-11
Recombinant Or Transgenic Factor Vii Composition, Each Factor Vii Molecule Having Two N-glycosylation Sites With Defined Glycan Units App 20090311239 - Chtourou; Abdessatar Sami ; et al.	2009-12-17
Method of measuring activation of effector cells Grant 7,595,165 - Romeuf , et al. September 29, 2	2009-09-29
Recombinant Or Transgenic Factor Vii Compound Having A Majority Of Glycan, Biantennary, Bisialylated And Non-fucosylated Forms App 20090239788 - Chtourou; Abdessatar Sami ; et al.	2009-09-24
Method for preparing monoclonal antibodies capable of activating effector cells expressing FC.gamma.RIII Grant 7,579,170 - Beliard , et al. August 25, 2	2009-08-25
Anti-rhesus D monoclonal antibodies Grant 7,541,029 - Beliard , et al. June 2, 2	2009-06-02
Therapeutic products with enhance ability to immunomodulate cell functions App 20070135621 - Bourel; Dominique ; et al.	2007-06-14
Correlation between the fucose content/galactose content ratio of anti-rhesus-d and anti-hla-dr antibodies and the adcc activity App 20070015239 - Bihoreau; Nicolas ; et al.	2007-01-18
Anti-Rhesus D monoclonal antibodies App 20070009522 - Beliard; Roland ; et al.	2007-01-11
Use of adcc-optimized antibodies for treating weak patients App 20060182741 - Bourel; Dominique ; et al.	2006-08-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.